- Home
- CYBN vs NVCT Comparison
CYBN vs NVCT Comparison
Compare CYBN & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYBN
- NVCT
- Stock Information
- Founded
- CYBN 2019
- NVCT 2020
- Country
- CYBN Canada
- NVCT United States
- Employees
- CYBN N/A
- NVCT N/A
- Industry
- CYBN Pharmaceuticals and Biotechnology
- NVCT Medicinal Chemicals and Botanical Products
- Sector
- CYBN Health Care
- NVCT Health Care
- Exchange
- CYBN Nasdaq
- NVCT Nasdaq
- Market Cap
- CYBN 147.4M
- NVCT 167.0M
- IPO Year
- CYBN N/A
- NVCT 2022
- Fundamental
- Price
- CYBN $5.66
- NVCT $5.96
- Analyst Decision
- CYBN Strong Buy
- NVCT Strong Buy
- Analyst Count
- CYBN 4
- NVCT 3
- Target Price
- CYBN $71.25
- NVCT $15.33
- AVG Volume (30 Days)
- CYBN 1.2M
- NVCT 109.6K
- Earning Date
- CYBN 11-13-2025
- NVCT 11-04-2025
- Dividend Yield
- CYBN N/A
- NVCT N/A
- EPS Growth
- CYBN N/A
- NVCT N/A
- EPS
- CYBN N/A
- NVCT N/A
- Revenue
- CYBN N/A
- NVCT N/A
- Revenue This Year
- CYBN N/A
- NVCT N/A
- Revenue Next Year
- CYBN N/A
- NVCT N/A
- P/E Ratio
- CYBN N/A
- NVCT N/A
- Revenue Growth
- CYBN N/A
- NVCT N/A
- 52 Week Low
- CYBN $4.81
- NVCT $4.44
- 52 Week High
- CYBN $11.39
- NVCT $11.52
- Technical
- Relative Strength Index (RSI)
- CYBN 41.21
- NVCT 46.64
- Support Level
- CYBN $5.52
- NVCT $5.86
- Resistance Level
- CYBN $6.30
- NVCT $6.24
- Average True Range (ATR)
- CYBN 0.32
- NVCT 0.31
- MACD
- CYBN -0.07
- NVCT -0.00
- Stochastic Oscillator
- CYBN 19.61
- NVCT 49.41
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.